CHICAGO, IL USA (UroToday) - The value of urodynamic studies (UDS) was assessed using secondary data analysis from the ValUE trial, a multicenter, non-inferiority, randomized trial involving 630 female patients.
Of this group, 294 of 315 subjects were randomized to UDS after an office evaluation had established a treatment plan. The research group sought to see how the UDS data influences changes in the treatment plan; a 57% change in diagnosis occurred after the evaluation of UDS data. Voiding phase dysfunction was the only type of diagnosis that showed an increase. BMI and voiding phase events were associated with the change in diagnosis.
As a result of the UDS data, surgery was cancelled in four patients, and one patient was changed to a different type of sling. Overall, there was a 14% change in the global treatment plan after UDS data was evaluated; however, the UDS-driven treatment plan was not associated with success and the UDS-driven treatment was associated with an increase incidence for UUI at 3-12 months post operatively.
The researchers concluded routine UDS evaluation if not necessary. In this study, the group did do an objective measurement of pelvic floor strength. Presented by H. E. Richter* at the annual American Urogynecologic Society (AUGS) 33rd Annual Scientific Meeting - October 3 - 6, 2012 - Hilton Chicago - Chicago, Illinois USA
* University of Alabama, Birmingham, AL USA
Reported for UroToday by Karen Roberts, Medical Editor
This year’s 33rd Annual Meeting of the American Urogynecologic Society (AUGS) is the largest gathering to date with an increase in abstracts (346) and video presentations (41). AUGS reports an overall membership increase at 1,500 members.